Abstract
With the expanded clinical use of Chromosome Microarray Analysis (CMA) to detect diagnostic, prognostic and therapeutic markers in cancer, there is a growing need for standardized, objective and evidence-based interpretation and reporting of CMA findings. Here we present the classification and reporting recommendations for acquired CNAs and CN-LOH regions in neoplastic disorders, created through collaboration between the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
